Oliver Kast, Head Business Development and Licensing and Computational Innovation at Boehringer Ingelheim, shared on LinkedIn:
“Deal number 2 with SBP Group. Another big one.
Very excited about our new multi-asset oncology partnership, bringing together ADC and T-cell engager programs and building on an already strong relationship between our teams.
And this is more than a transaction – it’s the next step in a partnership that has continued to grow.
A big thank you to everyone who helped get us here. Now the truly exciting part begins. Working together with the SBP team to turn the science into potential cancer treatments that can make a difference for patients.
Looking forward to the journey ahead!”
Boehringer Ingelheim, added:
“We’re entering a partnership with SBP Group to advance potential next-generation cancer treatments, with the aim of turning promising science into new treatment possibilities for people living with difficult-to-treat cancers.
The partnership will explore multiple early-stage antibody-drug conjugate (ADC) and T-cell engager programs.
- ADCs are designed to deliver treatment more directly to cancer cells
- T-cell engagers are designed to help T cells, a type of immune cell, recognize and attack cancer cells
Building on our existing relationship, we’re combining SBP Group’s innovative platforms and early-development capabilities with our global oncology expertise.”
Additional information about Boehringer Ingelheim’s first collaboration with SBP Group
- April 2024: Boehringer Ingelheim and SBP Group established a strategic oncology partnership focused on developing and commercializing Boehringer’s innovative cancer medicines in mainland China.
- Boehringer’s contribution: The collaboration included oncology assets such as zongertinib, brigimadlin, and obrixtamig.
- Clinical progress: These assets advanced through clinical development, with zongertinib subsequently receiving FDA accelerated approval in August 2025 for previously treated HER2-mutant advanced NSCLC.
- November 2026: The companies announced a new partnership in the opposite direction, with SBP Group licensing six preclinical biologic programs to Boehringer Ingelheim for international development, expanding their collaboration beyond the original China-focused agreement.
You may also be interested in: